Skip to main content
CTKB logo

CTKB · Cytek Biosciences, Inc. · Investor Relations

Track CTKB — free
$6.12 +0.20 (+3.46%) Play latest call Q3 2026 earnings call transcript
Market Cap
$774.24M
Shares
130.78M
Volume · Nov 19 289.07K Avg daily vol (3M) 1.27M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-02 21:30 UTC Piper Sandler 38th Annual Healthcare Conference Conference

Recent news

Date Headline
2026-11-18 Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences: Evercore 9 th Annual Healthcare Conference in Miami, FL CEO Wenbin Jiang and

2026-11-05 Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year

FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora ® Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards.

2026-11-04 Cytek Biosciences Reports Third Quarter 2026 Financial Results

FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026. Recent Highlights Total revenue for the third

2026-10-29 Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL CFO William

2026-10-21 Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026.

2026-09-23 Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the expansion of its Cytek ® Cloud digital ecosystem with a new

2026-09-09 Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc.

2026-09-03 Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading

2026-09-01 Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. Wells Fargo 21 st Annual Healthcare Conference in Boston, MA CFO William

2026-08-21 Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in

2026-08-05 Cytek Biosciences Reports Second Quarter 2026 Financial Results

FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter

2026-07-22 Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026

FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026.

2026-07-15 Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to

2026-06-10 Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference

FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upcoming Singular Research’s Las Vegas Invitational Conference taking place June 14-16, 2026.

2026-06-02 Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026

New 7-Laser Cytek Borealis™ System With Deep Ultraviolet and Infrared cFluor® Reagents; Cytek Aurora™ Evo System Enhancements for Automation and Workflow Efficiency FREMONT, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- At CYTO 2026, the industry’s premier flow cytometry conference, spectral flow

2026-05-07 Cytek Biosciences Reports First Quarter 2026 Financial Results

FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Total revenue for the first quarter of

2026-04-23 Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. The company’s management will webcast a

2026-03-09 Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact

Anniversary Milestone Highlights Expanded Manufacturing Capacity, Stronger Asia-Pacific Presence, and Measurable Contributions to Global Supply Chain Resilience FREMONT, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- One year after opening its 8,500-square-foot Singapore facility, spectral flow

2026-02-26 Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025.

2026-02-18 Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference

FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46 th Annual Health Care Conference in Boston, MA.

2026-02-12 Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 26, 2026.

2026-01-12 Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

Company to present at the 44th Annual JP Morgan Healthcare Conference FREMONT, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year

2025-11-12 TIME Recognizes Cytek® Biosciences as One of America’s Growth Leaders of 2026

FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME’s 2026 list of America’s Growth Leaders. Presented in partnership with global data firm Statista, the inaugural ranking recognizes the

Past events

Source: https://investors.cytekbio.com/

Key facts CIK 1831915 CUSIP 23285D109 13F (30d) 155 filings 138 filers Visit website Investor relations